Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Aspirin Use for Heart Disease Prevention May Benefit Those with Coronary Artery Calcium Deposits

By BiotechDaily International staff writers
Posted on 21 May 2014
Image: Figure A shows the location and angle of the coronary calcium scan image. Figure B is a coronary calcium scan image showing calcifications in a coronary artery (Photo courtesy of the [US] National Heart, Lung, and Blood Institute).
Image: Figure A shows the location and angle of the coronary calcium scan image. Figure B is a coronary calcium scan image showing calcifications in a coronary artery (Photo courtesy of the [US] National Heart, Lung, and Blood Institute).
A recent study found that taking aspirin to prevent heart disease benefits individuals with high coronary artery calcium (CAC) scores but can actually cause damage from bleeding in individuals with low levels of coronary artery calcium.

An individual's CAC score is determined by using computerized tomography (CT) to scan the coronary blood vessels. Calcium deposits show up as bright white spots on the scan.

Investigators at the Minneapolis Heart Institute (MN, USA) monitored 4,229 individuals participating in the Multi-Ethnic Study of Atherosclerosis (MESA) at six centers in the USA. Participants had no known CVD (cardiovascular disease) or diabetes, were not on aspirin therapy, and were followed for approximately seven years.

Results revealed that participants with elevated CAC scores (greater than 100) were two to four times more likely to benefit from aspirin therapy than to be harmed, even if they did not qualify for aspirin use according to current American Heart Association guidelines. Conversely, MESA participants with no calcified plaque (CAC score = zero) were two to four times more likely to be harmed by aspirin use than to benefit.

“We estimate that individuals with significant plaque buildup in the arteries of the heart are much more likely to prevent a heart attack with aspirin use than to suffer a significant bleed,” said first author Dr. Michael D. Miedema, a preventative cardiologist at the Minneapolis Heart Institute. “On the opposite end of the spectrum, if you do not have any calcified plaque, our estimations indicate that use of aspirin would result in more harm than good, even if you have risk factors for heart disease such as high cholesterol or a family history of the disease.”

“A CAC score of zero is associated with a very low risk of having a heart attack. That means individuals with a score of zero may not benefit from preventive medications, such as aspirin as well as the cholesterol-lowering statin medications. Approximately 50% of middle-aged men and women have a CAC score of zero, so there is a potential for this test to personalize the approach to prevention and allow a significant number of patients to avoid preventive medications, but we need further research to verify that routine use of this test is the best option for our patients.”

The study was published in the May 6, 2014, online edition of the journal Circulation: Cardiovascular Quality and Outcomes.

Related Links:

Minneapolis Heart Institute



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.